Formerly dba Triad Pharmaceuticals, Inc., management changed the name to Arisaph Pharmaceuticals, Inc. in November, 2005. Arisaph Pharmaceuticals, Inc., is a biopharmaceutical company,organized around developing therapies for cancer, cardiovascular disease, and diabetes. The company utilizes proprietary drug discovery platforms to develop differentiated medicines that are highly potent and act on select targets. Arisaph has had seven active drug discovery programs in various stages of preclinical development. The firm's products include new chemical entities (NCEs) such as dipeptidylpeptidase IV inhibitors, stable GLP-1 agonists, HDL modulators and plaque reducers, and tumor activated pro-soft drugs.
